Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer: a single technology appraisal.

CRD and CHE Technology Assessment Group, Mark Rodgers, Marta O Soares, D. Epstein, Huiqin Yang, Alison Jane Eastwood

Research output: Book/ReportOther report

Original languageEnglish
PublisherCentre for Reviews and Dissemination/ Centre for Health Economics
Publication statusPublished - 2010

Cite this